Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical ICPT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | -0.66% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/11/2020
- Sector: Healthcare
- Industry: Biotechnology
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Medical Specialties Diabetes Gastroenterology Hepatology Digestive Diseases Fibrosis Primary Biliary Cholangitis Bile Acid Chronic Liver Diseases Obeticholic Acid
Medical Specialties Diabetes Gastroenterology Hepatology Digestive Diseases Fibrosis Primary Biliary Cholangitis Bile Acid Chronic Liver Diseases Obeticholic Acid
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 125.0 |
| 52 Week Low | 47.57 |
| Average Volume | 667,586 |
| 200-Day Moving Average | 83.38 |
| 50-Day Moving Average | 75.19 |
| 20-Day Moving Average | 83.11 |
| 10-Day Moving Average | 81.79 |
| Average True Range | 5.40 |
| ADX | 21.82 |
| +DI | 24.01 |
| -DI | 31.84 |
| Chandelier Exit (Long, 3 ATRs ) | 79.77 |
| Chandelier Exit (Short, 3 ATRs ) | 85.76 |
| Upper Bollinger Band | 95.30 |
| Lower Bollinger Band | 70.93 |
| Percent B (%b) | 0.05 |
| BandWidth | 29.32 |
| MACD Line | -0.74 |
| MACD Signal Line | 1.45 |
| MACD Histogram | -2.1957 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 77.97 | ||||
| Resistance 3 (R3) | 77.70 | 75.52 | 77.02 | ||
| Resistance 2 (R2) | 75.52 | 74.07 | 75.66 | 76.70 | |
| Resistance 1 (R1) | 73.89 | 73.17 | 72.81 | 74.16 | 76.38 |
| Pivot Point | 71.72 | 71.72 | 71.17 | 71.85 | 71.72 |
| Support 1 (S1) | 70.09 | 70.26 | 69.00 | 70.36 | 68.14 |
| Support 2 (S2) | 67.91 | 69.37 | 68.05 | 67.82 | |
| Support 3 (S3) | 66.28 | 67.91 | 67.50 | ||
| Support 4 (S4) | 66.55 |
